Array BioPharma (ARRY) PT Raised to $35 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.39 -4.78%
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff raised the price target on Array BioPharma (NASDAQ: ARRY) to $35.00 (from $28.00) while maintaining a Overweight rating.
- BEACON Interim Analysis Hits, sNDA Filing in 2H:19
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oil States International (OIS) PT Lowered to $11 at Raymond James
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
